$Cytokinetics (CYTK.US)$ Cytokinetics (CYTK) and Bayer have ...

Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and joint development plans, with Bayer conducting Phase 3 trials for obstructive HCM in Japan while Cytokinetics expands its ACACIA-HCM and CEDAR-HCM trials into the region.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

11K Views

Comment

Sean Parker

I love trading and don't mind helping if you have reasonable questions. I don't give buy/sell advice, only ideas to help

572

Followers

Following

2882

Visitors

Market Insights

Popular Gold Mining Stocks Popular Gold Mining Stocks

Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave. Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave.

No. Symbol 5D % Chg

International Tower Hill Mines

THM